Editas Medicine, Inc. (EDIT)
NASDAQ: EDIT · Real-Time Price · USD
3.380
+0.180 (5.63%)
At close: Oct 4, 2024, 4:00 PM
3.320
-0.060 (-1.78%)
After-hours: Oct 4, 2024, 7:00 PM EDT
Editas Medicine Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for Editas Medicine stock have an average target of 10.5, with a low estimate of 7.00 and a high estimate of 15. The average target predicts an increase of 210.65% from the current stock price of 3.38.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for EDIT stock from 11 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '24 | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 5 | 4 |
| Buy | 2 | 1 | 1 | 1 | 0 | 0 |
| Hold | 6 | 6 | 6 | 6 | 7 | 7 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 11 | 11 | 11 | 12 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Hold Reiterates $8 | Hold | Reiterates | $8 | +136.69% | Sep 19, 2024 |
| Jones Trading | Jones Trading | Strong Buy Initiates $13 | Strong Buy | Initiates | $13 | +284.62% | Sep 17, 2024 |
| Barclays | Barclays | Hold Maintains $9 → $7 | Hold | Maintains | $9 → $7 | +107.10% | Aug 8, 2024 |
| Truist Securities | Truist Securities | Strong Buy Maintains $20 → $12 | Strong Buy | Maintains | $20 → $12 | +255.03% | Aug 8, 2024 |
| B of A Securities | B of A Securities | Hold → Strong Buy Upgrades $13 → $15 | Hold → Strong Buy | Upgrades | $13 → $15 | +343.79% | Aug 8, 2024 |
Financial Forecast
Revenue This Year
30.79M
from 78.12M
Decreased by -60.59%
Revenue Next Year
18.22M
from 30.79M
Decreased by -40.82%
EPS This Year
-2.98
from -2.02
EPS Next Year
-2.83
from -2.98
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 66.3M | 38.9M | 254.1M | ||
| Avg | 30.8M | 18.2M | 48.1M | ||
| Low | 2.9M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -15.2% | 26.2% | 1,294.8% | ||
| Avg | -60.6% | -40.8% | 163.8% | ||
| Low | -96.2% | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.51 | -2.21 | -1.77 | ||
| Avg | -2.98 | -2.83 | -2.75 | ||
| Low | -3.32 | -3.67 | -4.37 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.